logo
Mysterious Signals From Deep Space Hint at Something Brutal, Scientists Say

Mysterious Signals From Deep Space Hint at Something Brutal, Scientists Say

Yahoo13-07-2025
Astronomers believe they've uncovered the source behind mysterious cosmic signals known as fast X-ray transients (FXTs) — and it adds a grim twist to our understanding of the death of stars.
Right as a massive star explodes in a supernova, it unleashes a tremendously energetic stream of particles called a jet, producing a gamma ray burst — one of the most powerful explosions in the universe. The rest of the star, typically, collapses into a black hole.
But a pair of new studies suggests that this last gasp by a star before winking out of existence can get "trapped" by some of the star's own remains, slamming the door shut on the jet so it can't fully shine.
"As the jet is being launched, that extra material from the star that didn't collapse into the black hole [interacts] with the jet in such a way that sort of suppresses the jet from actually breaking out of the outer layers," Jillian Rastinejad, an astronomer at Northwestern University and lead author of one the two studies set to published in the The Astrophysical Journal Letters, told Gizmodo.
That produces the weaker X-ray emissions, in the form of an FXT, which can last from seconds to hours.
The nickname astronomers have for these weakened blasts is nearly as brutal as the catastrophic event itself: a "failed" jet.
According to the findings, FXTs arise from a type of stellar explosion called a Type Ic supernova, which occurs in stars that have long shed their outermost layers of hydrogen and helium.
Because of their ephemeral nature and the extreme distance of most detected FXTs to date, pinpointing their origins has been a challenge for astronomers.
Rastinejad and her team's breakthrough came when data collected in the Einstein Probe, an X-ray telescope program run by the Chinese Academy of Sciences in collaboration with the European Space Agency, revealed an FXT that was unusually close to Earth — a mere 2.8 billion light years away.
Dubbed EP 250108a, telescopes including the Keck Observatory in Hawai'i and the James Webb Space Telescope rushed to extensively image the X-ray burst in multiple wavelengths, collecting infrared and optical data.
"It's important to note that X-ray data alone cannot tell us what phenomena created an FXT," Rastinejad said in a statement about the work. "Rapid observations of the location of the FXT at optical and infrared wavelengths are key to identifying the aftermath of an FXT and assembling clues to its origin."
With that wealth of data, the astronomers were able to observe how the signal evolved over time. Over the course of several weeks, the stunted supernova increased in brightness before eventually fading. The brief peak in brightness allowed the astronomers to determine that the blast was a Type Ic supernova — and one that was clearly lacking a gamma ray burst.
This has profound implications for our understanding of a star's demise, because according to the work, with sufficiently large stars — the one that produced EP 250108a is estimated to be between 15 to 30 times heavier than the Sun — the full-blown gamma ray bursts we've come to equate with supernovas may not actually be the norm.
Instead, Rastinejad said, "this 'trapped' jet outcome is more common in massive star explosions than jets that successfully emerge from the star."
More on space: Astronomers Capture First-Ever Image of Star That Exploded Twice
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Plexision Secures Funding to Bring Artificial Intelligence to Transplant Outcome Care
Plexision Secures Funding to Bring Artificial Intelligence to Transplant Outcome Care

Yahoo

time25 minutes ago

  • Yahoo

Plexision Secures Funding to Bring Artificial Intelligence to Transplant Outcome Care

New investment to advance personalized transplant medicine using AI-enhanced cell-based testing PITTSBURGH, July 24, 2025--(BUSINESS WIRE)--Plexision, a biotechnology company, today announced a $365,000 investment from the Richard King Mellon Foundation. The funds will be used to accelerate the integration of artificial intelligence (AI) and machine learning (ML) capabilities across Plexision's suite of cell-based blood tests, significantly improving predictive accuracy for complex transplant outcomes. Despite advances in transplant medicine, managing immunosuppressive drugs remains a delicate balance. Too little medication can lead to rejection, which can be cell- or antibody-mediated, while too much can increase the risk of infections with different viruses, and in some cases, lymphoma related to Epstein-Barr virus (EBV). Legacy testing tools on the market offer limited visibility into a patient's immune status, and provide reactive, binary results. To distinguish between the various types of rejection and infection, clinicians often integrate other clinical data to make treatment decisions. Plexision's blood tests predict the most common rejection subtypes and post-transplant infections, all using a common platform of immune cell function. When integrated with machine learning, this test panel ranks risks of multiple outcomes across an outcome category in each patient, including the likelihoods of stable graft function, and T-cell-mediated and antibody-mediated rejection. This approach also identifies the presence or absence of an infection, including infection-related lymphoma. These capabilities have been developed and validated in multi-center studies to be reported at the World Transplant Congress in San Francisco, CA between August 2-6, 2025. "Plexision is redefining transplant diagnostics by predicting rejection subtypes and infection risks using blood tests derived from a single immune cell function platform," said Dr. Rakesh Sindhi, a transplant surgeon, Co-founder and Chief Scientific Officer, Plexision. The expanded use of AI will enhance the platform's ability to rank and predict the likelihood of multiple outcomes in each patient, making it a powerful clinical decision support tool for caregivers delivering precision transplant medicine. The company's proprietary technology delivers results in as little as 6 to 24 hours, enabling timely intervention. "This funding enables us to take the next step in making transplant care truly personalized. By expanding our artificial intelligence and machine learning capabilities, we are transforming how clinicians will interpret immunologic signals, moving from singular binary 'yes/no' answers to ranked predictions tailored to each patient," added Sindhi. All tests are performed at Plexision's CLIA-approved and CAP-accredited reference laboratory in Pittsburgh, PA, using blood samples shipped in from clinical partners. Results are used with other clinical data to optimize management of individual transplant patients. Plexision's innovations have demonstrated strong clinical performance. For example, the company's PlexABMR™ test recently predicted antibody-mediated rejection in kidney transplant recipients with 81% positive predictive value and 75% negative predictive value in a multi-center trial. Another test predicted EBV infection, a cause of life-threatening infection-related lymphoma in transplant patients. These findings will also be featured at the 2025 World Transplant Congress. To learn more about Plexision, visit or email info@ to schedule a meeting with the company at the World Transplant Congress. About Plexision Plexision's reference laboratory performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. Transplant rejection testing services include the FDA-approved Pleximmune™ blood test to predict transplant rejection in children with liver or intestine transplants, the lab-developed Pleximark™ test to predict kidney transplant rejection, and the recently developed PlexABMR™ to predict antibody-mediated rejection. Tests that predict infection includes the lab-developed PlexCMV™, currently the most sensitive test to capture protective cell-mediated immunity in high-CMV-risk transplants. The PlexEBV™ test predicts EBV infection, which can cause post-transplant lymphoma. These tests measure cell-mediated immunity to cytomegalovirus and EBV, respectively. Plexision also performs custom R & D projects that require integration of cellular biomarker targets in all phases of development of drugs, vaccines, and gene therapy products, from pre-clinical to post-marketing. The company's portfolio of cell-based blood tests can be adapted to assess disease risk for several immunological disorders and develop personalized dosing recommendations. The company's reference laboratory in Pittsburgh, PA, is CLIA-approved, CAP-accredited and GMP-compliant. To learn more, visit or email info@ About Richard King Mellon Foundation Founded in 1947, the Richard King Mellon Foundation is the largest foundation in Southwestern Pennsylvania, and one of the 50 largest in the world. The Foundation's 2023 year-end net assets were $2.9 billion, and its Trustees in 2023 disbursed more than $176 million in grants and program-related investments. The Foundation focuses its funding on six primary program areas, delineated in its 2021-2030 Strategic Plan. View source version on Contacts Jason VancuraMarketbridge for Plexisionjvancura@

Humans Counted 8,600 Earthquakes in Yellowstone. AI Says We're Not Even Close
Humans Counted 8,600 Earthquakes in Yellowstone. AI Says We're Not Even Close

Gizmodo

time26 minutes ago

  • Gizmodo

Humans Counted 8,600 Earthquakes in Yellowstone. AI Says We're Not Even Close

Before the advent of artificial intelligence, experts often detected earthquakes by analyzing seismic data by hand. Unsurprisingly, this approach takes a long time, is cost-intensive, and usually identifies fewer earthquakes. Machine learning has now changed virtually everything. Using artificial intelligence, researchers have retroactively identified and assigned magnitudes to ten times as many seismic events in historical earthquake data from the Yellowstone caldera from 2008 to 2022 as had been previously registered. 'If we had to do it old school with someone manually clicking through all this data looking for earthquakes, you couldn't do it. It's not scalable,' Western University engineer Bing Li explained in a university statement. 'We leverage leading-edge deep learning algorithms and a detailed three-dimensional velocity model to construct a 15-year high-resolution earthquake catalog of the Yellowstone caldera region,' Li and colleagues explained in their study, published earlier this month in the journal Science Advances. Thanks to this approach, Yellowstone caldera's earthquake data from 2008 to 2022 now consists of 86,276 earthquakes, all of which strengthen seismologists' understanding of volcanic and seismic systems. Calderas, like Yellowstone's, are essentially ancient volcanoes that erupt and then collapse into their emptied magma chamber, leaving a large depression in the land. Many features related to volcanoes can cause earthquakes, and most of the ones at Yellowstone are brittle-failure events—when stress in the crust causes rocks to break. The study found that over half of Yellowstone's earthquakes are part of earthquake swarms—sequences of earthquakes that don't follow the mainshock-aftershock seismic pattern that most people are familiar with. 'While Yellowstone and other volcanoes each have unique features, the hope is that these insights can be applied elsewhere,' said Li, who is also an expert in fluid-induced earthquakes and rock mechanics. 'By understanding patterns of seismicity, like earthquake swarms, we can improve safety measures, better inform the public about potential risks and even guide geothermal energy development away from danger in areas with promising heat flow.' According to the study, earthquake swarms beneath the Yellowstone caldera took place along more immature fault structures—underdeveloped faults that have accumulated fewer 'slips' than mature fault structures. Myanmar's Devastating Earthquake in March Split the Earth at 'Supershear Velocity' While researchers expect more aftershocks along immature faults, 'to a large extent, there is no systematic understanding of how one earthquake triggers another in a swarm. We can only indirectly measure space and time between events,' said Li. 'But now, we have a far more robust catalogue of seismic activity under the Yellowstone caldera, and we can apply statistical methods that help us quantify and find new swarms that we haven't seen before, study them, and see what we can learn from them.' It goes to show that even the world's first national park still has secrets in store for researchers—like a brand new hole that recently opened up in Yellowstone's Norris Geyser Basin.

Vistagen to Present at the BTIG Virtual Biotechnology Conference
Vistagen to Present at the BTIG Virtual Biotechnology Conference

Yahoo

timean hour ago

  • Yahoo

Vistagen to Present at the BTIG Virtual Biotechnology Conference

SOUTH SAN FRANCISCO, Calif., July 24, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact your BTIG representative. To join the conference, email uscorporateaccess@ About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, such as vasomotor symptoms (hot flashes) associated with menopause. Connect at View source version on Contacts Investor Inquiries: Mark A. McPartlandmarkmcp@ Media Inquiries: Michelle P. Wellingtonmwellington@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store